Pathologists' staging of multiple foci of lung cancer: Poor concordance in absence of dramatic histologic or molecular differences

American Journal of Clinical Pathology

Volumn 143, Issue 5, 2015, Pages 701-706

  Homer, Robert J ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

Interobserver variation; Lung cancer; Multifocal lung cancer; Staging

Indexed keywords

MOLECULAR MARKER;

ARTICLE; CANCER STAGING; HISTOPATHOLOGY; HUMAN; LUNG CANCER; PATHOLOGIST; PRIORITY JOURNAL; UNCERTAINTY; INFORMATION PROCESSING; LUNG TUMOR; MALE; MIDDLE AGED; NON SMALL CELL LUNG CANCER; OBSERVER VARIATION; PATHOLOGY;

CARCINOMA, NON-SMALL-CELL LUNG; DATA COLLECTION; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; OBSERVER VARIATION;

EID: 84937133275     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPNBWF55VGKOIW     Document Type: Article

References (25)

1. Edge SB, Byrd DR, Compton CC, et al. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010.
2. College of American Pathologists. Cancer protocol templates. www.cap.org/cancerprotocols. Accessed October 1, 2014.
3. Martini N, Melamed MR. Multiple primary lung cancers. J Thorac Cardiovasc Surg. 1975;70:606-612.
4. Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6:244-285.
5. Fonseca A, Detterbeck FC. How many names for a rose: inconsistent classification of multiple foci of lung cancer due to ambiguous rules. Lung Cancer. 2014;85:7-11.
6. Lin MW, Wu CT, Kuo SW, et al. Clinicopathology and genetic profile of synchronous multiple small adenocarcinomas: implication for surgical treatment of an uncommon lung malignancy. Ann Surg Oncol. 2014;21:2155-2162.
7. Takamochi K, Oh S, Matsuoka J, et al. Clonality status of multifocal lung adenocarcinomas based on the mutation patterns of EGFR and K-ras. Lung Cancer. 2012;75:313-320.
8. Warth A, Macher-Goeppinger S, Muley T, et al. Clonality of multifocal nonsmall cell lung cancer: implications for staging and therapy. Eur Respir J. 2012;39:1437-1442.
9. Cortot AB, Italiano A, Burel-Vandenbos F, et al. KRAS mutation status in primary nonsmall cell lung cancer and matched metastases. Cancer. 2010;116:2682-2687.
10. Kalikaki A, Koutsopoulos A, Trypaki M, et al. Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC. Br J Cancer. 2008;99:923-929.
11. Girard N, Deshpande C, Azzoli CG, et al. Use of epidermal growth factor receptor/Kirsten rat sarcoma 2 viral oncogene homolog mutation testing to define clonal relationships among multiple lung adenocarcinomas: comparison with clinical guidelines. Chest. 2010;137:46-52.
12. Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med. 2013;137:828-860.
13. Marchevsky AM. Problems in pathologic staging of lung cancer. Arch Pathol Lab Med. 2006;130:292-302.
14. Detterbeck FC, Postmus PE, Tanoue LT. The stage classification of lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143:e191S-e210S.
15. Detterbeck FC. Synchronous, separate, and similar. J Thorac Oncol. 2010;5:150-152.
16. Yoshikawal T, Aoyagi Y, Kodama K, et al. Topographical distribution of allelic loss in individual lung adenocarcinomas with lymph node metastases. Mod Pathol. 2004;17:204-213.
17. Iijima H, Tomizawa Y, Dobashi K, et al. Allelic losses on chromosome 3p are accumulated in relation to morphological changes of lung adenocarcinoma. Br J Cancer. 2004;91:1143-1148.
18. Girard N, Deshpande C, Lau C, et al. Comprehensive histologic assessment helps to differentiate multiple lung primary nonsmall cell carcinomas from metastases. Am J Surg Pathol. 2009;33:1752-1764.
19. Battafarano RJ, Meyers BF, Guthrie TJ, et al. Surgical resection of multifocal non-small cell lung cancer is associated with prolonged survival. Ann Thorac Surg. 2002;74:988-993.
20. Roberts PF, Straznicka M, Lara PN, et al. Resection of multifocal non-small cell lung cancer when the bronchioloalveolar subtype is involved. J Thorac Cardiovasc Surg. 2003;126:1597-1602.
21. Shrager JB. Approach to the patient with multiple lung nodules. Thorac Surg Clin. 2013;23:257-266.
22. Moffatt-Bruce SD, Ross P, Leon ME, et al. Comparative mutational profiling in the assessment of lung lesions: should it be the standard of care? Ann Thorac Surg. 2010;90:388-396.
23. Wang X, Wang M, MacLennan GT, et al. Evidence for common clonal origin of multifocal lung cancers. J Natl Cancer Inst. 2009;101:560-570.
24. Mitsudomi T, Yatabe Y, Koshikawa T, et al. Mutations of the P53 tumor suppressor gene as clonal marker for multiple primary lung cancers. J Thorac Cardiovasc Surg. 1997;114:354-360.
25. Huang J, Behrens C, Wistuba I, et al. Molecular analysis of synchronous and metachronous tumors of the lung: impact on management and prognosis. Ann Diagn Pathol. 2001;5:321-329.